Connect with us

Featured

Here’s What You Missed 4/3/19

Daniel Chase

Published

on

stock_price_news

Few people realize that there’s a distinct difference between hearing and listening when someone is speaking to them. Hearing takes place when you recognize sound coming from a person’s mouth and the sound is processed through your ears, but this doesn’t necessarily mean that you actually listened to what someone said. To truly hear someone is to let them finish speaking and show, through body language and eye contact, that you’re paying attention. I’ve found that when I’m speaking to someone and I’ve finished speaking, if they ask me a specific question or share a thought that relates to what I said, I know they listened. Effective communication starts with good listening, and I would go so far as to say that it’s crucial for strong relationships. If you find yourself responding immediately to someone who’s said something, this means you were trying to figure out what to say while they were still speaking. 

I hope you listened to what I had to say, but here’s what you missed in the news yesterday. 

Borders Are Bad For Business, Beats, Battlestar Galactica 

According to a recent economic study released on Tuesday, countless American businesses, including manufacturers and farmers, will lose $726 million per day if President Donald Trump makes good on his threat to temporarily shutdown the US-Mexico border. Chat Moutray, chief economist at the National Association of Manufacturers told The Hill that over 21,000 companies in the U.S. export to Mexico.

“The NAM has been to the border to witness the situation firsthand. Congress absolutely must tackle comprehensive immigration reform immediately to address the real national security and humanitarian concerns that are a direct result of our current broken system. We’re getting somewhat mixed messages from the markets right now. We have really strong job growth, optimism is high when I talk to firms about their overall outlook, but they also have this lingering worry about the global economy, and looking at Germany and China, we’re already seeing materially slower growth than even a couple of months ago.”

Chad Moutray

Bern, Baby Bern That Money!

Sen. Bernie Sanders (D-VT) is back at it again with the white hairs and is showing no signs of slowing down. Sanders in February announced his entrance into the pantheon of candidates running for president in the 2020 election. According to recent reports, he’s raised $18.2 million from over five-hundred thousand donors since his initial announcement. If these numbers are in fact correct, Sander has raised more money than any other Democratic presidential candidate currently in the running. 

Compared to other candidates like Sen. Kamala Harris, Sanders has raised most of his funds from smaller donors rather than deep-pocketed individuals. 

“We’re building a campaign to win and we’re planning to win from the outset.”

Faiz Shakir, Campaign Manager for Sanders 2020

Continue Reading
Click to comment

Biotechnology

Acadia (ACAD) Stock Price is up 60% This Month; Bullish Signal For Biotechs?

Joe Samuel

Published

on

One sector that has always been a favorite of investors of all varieties is the pharmaceutical sector and all investors like a turnaround story. Over the years, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had been one of the better-known strugglers in the industry. That was reflected in the stock price as well. But recent developments have breathed new life in the stock, which could be an indicator for the biotech industry at large.

Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)

There has been no lack of attention on biotech penny stocks this year.  At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes. 

The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods.  For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.

On September 12, PharmaCyte saw more than 4 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.

Second, the company has been ramping up for a much-anticipated shareholder update call on September 20. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to treat locally advanced, inoperable pancreatic cancer and developments related to PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release.

Acadia (ACAD) Stock Price: Important Developments

People who had held on to the stock through the barren years got a nice boost recently. This came after Acadia’s well-known medicine Nuplazid recorded better than expected sales. In addition to that, there were encouraging results from a dementia-driven psychosis study. Hence, it is important to figure out whether it is perhaps time to buy the stock.

While the signs are no doubt encouraging, it is important to note that data reveals that around 60,000 people in the United States are diagnosed with Parkinson’s every year. Out of those, a large proportion (50% to 80%) suffers from dementia. Hence it can be argued that the market is simply not too big for Acadia’s Nuplazid.

Moreover, different types of dementia are brought on by Alzheimer’s disease, which is why all of it might not actually fall into Acadia’s lap. That being said, it is also well known that antipsychotic drugs have only been approved for the treatment of Parkinson’s and hence the Alzheimer’s market is already out of the question.

Market Potential

Projections suggest that the sale of Nuplazid could grow to more than $1 billion in 2023 from $224 million in 2018. While that is encouraging, it is also important to note that the growth has been priced into the Acadia stock price.

However, if Acadia’s plans for growth somehow run into any trouble, then there is every chance of the stock price plummeting once again. The company is recovering and there is some time before the patient population for Nuplazid can be expanded sufficiently. In the meantime, investors need to be a bit more patient.

Shares of ACAD are up over 60% over the past week and made a new multi-year high of $43.98.

biotech stock price
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Featured

Advanced Micro Devices (AMD) Stock Price Consolidates After the Recent Rally: What Next?

Jon Phillip

Published

on

technology stocks

It sometimes so happens that the price action and activity around a stock reaches a decisive stage, from which it can go only one way or another. In other words, it is the moment when the future of a stock is a straight shootout between the bulls and the bears.

The Advanced Micro Devices, Inc. (NASDAQ:AMD) stock has now reached such a stage according to keen observers and hence the stock is now trading within a very narrow range as the squeeze continues. In such a situation, it is only natural for investors to wonder which way this whole thing is going to go in the short term.

Key Analysis

First and foremost, it is important to point out that since Lisa Su took over as the Chief Executive Officer in 2014, AMD has managed to stage a remarkable turnaround. Although the process has been slow, it proved to be highly lucrative for those investors who were patient. The stock has risen steadily over the past three years and rallied from $2 to around $30.

However, at the time, the investors had backed the company’s turnaround but now the story has changed and the turnaround has concluded. The bulls seem to think that the run is going to continue while bears believe that with the conclusion of the turnaround, the stock is all set to fall.

After all, if there is no further upside, then there is no point in holding the stock. This has caused uncertainty in the stock and its price action. Analysts believe that while the turnaround story had resulted in enormous gains for many investors, the stock is now expected to mirror the performance of the broader market. This factor lays credence to the bears’ position and moreover, the small matter of a looming Presidential election needs to be considered as well. Markets are generally flat in the lead-up and hence, analysts believe that although AMD might continue to be range-bound, it is unlikely that it is going to go on a rally.

Continue Reading

Featured

Stock Price Newsletter – September 18, 2019

Joe Samuel

Published

on

biotech stock to watch 2019

4 Penny Stocks Catching Attention This Week

Several economic and sector events have sparked interest in a number of small-cap and micro-cap stocks this week.

See For Yourself


Airline Stocks In Focus; Spur Interest In Detection Tech Companies?

The latest mix of attacks and focus on airlines could have a different impact on sectors like weapons detection & defense. What could this mean for stocks to watch this week?

Click Here To Read More


Top Biotech Stocks To Watch This Week

The values of biotech equities, however, do generally start to pick up as the year winds down. The underlying reason is that the latter part of the year is chock-full of key data readouts, regulatory decisions, and thousands of scientific conferences across the globe. 

Click Here To Read More

Click Here For Full Disclaimer

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com